Publisher | Google Scholor Prete R, Long SL, Gallardo AL, Gahan CG, Corsetti A, et al
The jump from 1mg to 4mg, nearly doubling the weight loss percentage, likely represents the addition of meaningful glucagon receptor engagement
PMID: 20534738
Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D) and established cardiovascular disease, yet remain underutilized in clinical practice
GLP-1 slows stomach emptying and can affect medicines that need to pass through the stomach quickly
You must also meet other criteria, such as documented history of failed weight loss attempts, and complete the prior authorization process